Abstract 657P
Background
Hiatal hernia (HH) is a risk factor for esophageal and junctional adenocarcinoma (EGJA). Its impact on the outcomes after EGJA surgery is unknown. Objectives were to evaluate complete tumor resection rate (primary objective), 30-day postoperative outcomes and survival (secondary objectives) in patients with a HH ≥ 5cm (HH group) compared to those who did not have a HH or presented with a HH
Methods
Among 367 patients who underwent surgery for EGJA, a HH was searched for on CT scan and barium swallow, with comparison between the HH (n = 42) and control (n = 325) groups.
Results
In the HH group, EGJAs exhibited higher rates of pN3 stages (28.5% vs. 10.1%, P = 0.002), of incomplete resection (50.0% vs. 4.0%, P
Conclusions
For the first time, we showed that a HH ≥5cm is associated with a poor prognosis in patients who had surgery for EGJA, linked to greater incomplete resection and lymph node involvement. Neoadjuvant radiotherapy was associated with a significant toxicity in patients with a HH ≥5cm.
Clinical trial identification
Legal entity responsible for the study
None
Funding
University Hospital of Lille
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Utility of algorithm-based chemoradioselection for advanced laryngeal and hypopharyngeal carcinoma
Presenter: Muneyuki Masuda
Session: Poster display
Resources:
Abstract
Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting
Presenter: Tera Eerkes
Session: Poster display
Resources:
Abstract
Uterine carcinosarcoma: a retrospective clinical cohort analysis
Presenter: Carla Perna
Session: Poster Display
Resources:
Abstract
Using mouse and human pancreatic organoids to infer resistance to targeted therapy
Presenter: Mariano Ponz-Sarvise
Session: Poster display
Resources:
Abstract
Using diffusion-weighted MRI derived apparent diffusion coefficient as a predictive biomarker of tumor response in non-Hodgkin lymphoma
Presenter: Siarhei Kharuzhyk
Session: Poster display
Resources:
Abstract
Use of treatments of questionable benefit in hospitalized patients with metastatic gastric or esophageal cancer near the end of life. A country-wide, register-based study
Presenter: Emmanuelle Kempf
Session: Poster display
Resources:
Abstract
Use of Oncotype DX Recurrence Score® (RS) reduces chemotherapy (CT) beyond treatment decisions using Ki67-based determinations of luminal A and B breast cancer subtypes: a retrospective study in the Spanish population
Presenter: Laura Garcia-Estevez
Session: Poster display
Resources:
Abstract
Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study
Presenter: Petra Pichler
Session: Poster display
Resources:
Abstract
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC). Part1: the ENCOURAGE cohort of 1158 patients (pts) by GINECO
Presenter: Dominique Berton-Rigaud
Session: Poster Display
Resources:
Abstract
Use and clinical impact of conventional cytotoxic chemotherapy (CTx) subsequent to immunotherapy in metastatic melanoma
Presenter: Eoghan Malone
Session: Poster display
Resources:
Abstract